N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2 H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

The Protein Data Bank

Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196

CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., & Karplus, M. (1983) · Journal of Computational Chemistry · doi:10.1002/jcc.540040211 · Cited by 14,944

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385

Crystal structure of the Src family tyrosine kinase Hck

Sicheri, F., Moarefi, I., & Kuriyan, J. (1997) · Nature · doi:10.1038/385602a0 · Cited by 1,172

Regulation of Protein Kinases

Nolen, B., Taylor, S., & Ghosh, G. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.08.024 · Cited by 1,167

Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors

Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., & Schlessinger, J. (1997) · Science · doi:10.1126/science.276.5314.955 · Cited by 1,097

The clinical course of bone metastases from breast cancer

Coleman, R., & Rubens, R. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.13 · Cited by 1,084

Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase

Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833

Structure and regulation of Src family kinases

Boggon, T. J., & Eck, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208081 · Cited by 712

Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection

Cavert, W., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z.-Q., Mills, R., McDade, H., et al. (1997) · Science · doi:10.1126/science.276.5314.960 · Cited by 622

Validation of the general purpose QUANTA ®3.2/CHARMm® force field

Momany, F. A., & Rone, R. (1992) · Journal of Computational Chemistry · doi:10.1002/jcc.540130714 · Cited by 579

Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation

Yamaguchi, H., & Hendrickson, W. A. (1996) · Nature · doi:10.1038/384484a0 · Cited by 492

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain

Mohammadi, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 482

Induction and regulation of epithelial–mesenchymal transitions

Boyer, B., Vallés, A. M., & Edme, N. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00427-5 · Cited by 436

Molecular Mechanism for the Regulation of Protein Kinase B/Akt by Hydrophobic Motif Phosphorylation

Yang, J., Cron, P., Thompson, V., Good, V. M., Hess, D., Hemmings, B. A., & Barford, D. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00550-6 · Cited by 418

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

Tong, L., Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Brown, M. L., & Pargellis, C. A. (1997) · Nature Structural Biology · doi:10.1038/nsb0497-311 · Cited by 387

Newest findings on the oldest oncogene; how activated src does it

Frame, M. C. (2004) · Journal of Cell Science · doi:10.1242/jcs.01111 · Cited by 367

The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma

Carlin, B. I., & Andriole, G. L. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.0.co;2-q · Cited by 363

Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling

Avizienyte, E., Wyke, A. W., Jones, R. J., McLean, G. W., Westhoff, M. A., Brunton, V. G., & Frame, M. C. (2002) · Nature Cell Biology · doi:10.1038/ncb829 · Cited by 362

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

Hennequin, L. F., Stokes, E. S. E., Thomas, A. P., Johnstone, C., Plé, P. A., Ogilvie, D. J., Dukes, M., Wedge, S. R., Kendrew, J., & Curwen, J. O. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011022e · Cited by 311

The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility

Fincham, V. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.81 · Cited by 289

The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase

Wilson, K. P., McCaffrey, P. G., Hsiao, K., Pazhanisamy, S., Galullo, V., Bemis, G. W., Fitzgibbon, M. J., Caron, P. R., Murcko, M. A., & Su, M. S. S. (1997) · Chemistry & Biology · doi:10.1016/s1074-5521(97)90194-0 · Cited by 274

Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2

Lawrie, A. M., Noble, M. E. M., Tunnah, P., Brown, N. R., Johnson, L. N., & Endicott, J. A. (1997) · Nature Structural Biology · doi:10.1038/nsb1097-796 · Cited by 268

Structural basis for selective inhibition of Src family kinases by PP1

Liu, Y., Bishop, A., Witucki, L., Kraybill, B., Shimizu, E., Tsien, J., Ubersax, J., Blethrow, J., Morgan, D. O., & Shokat, K. M. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80118-5 · Cited by 252

Design and Structure−Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors

Hennequin, L. F., Thomas, A. P., Johnstone, C., Stokes, E. S. E., Plé, P. A., Lohmann, J.-J. M., Ogilvie, D. J., Dukes, M., Wedge, S. R., Curwen, J. O., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990345w · Cited by 241

Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase

Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., & Kuyper, L. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990401t · Cited by 233

High-Resolution Crystal Structures of Human Cyclin-Dependent Kinase 2 with and without ATP: Bound Waters and Natural Ligand as Guides for Inhibitor Design

Schulze-Gahmen, U., De Bondt, H. L., & Kim, S.-H. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960402a · Cited by 211

Chromatin loops are selectively anchored using scaffold/matrix-attachment regions

Heng, H. H. Q., Goetze, S., Ye, C. J., Liu, G., Stevens, J. B., Bremer, S. W., Wykes, S. M., Bode, J., & Krawetz, S. A. (2004) · Journal of Cell Science · doi:10.1242/jcs.00976 · Cited by 204

Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis

McTigue, M. A., Wickersham, J. A., Pinko, C., Showalter, R. E., Parast, C. V., Tempczyk-Russell, A., Gehring, M. R., Mroczkowski, B., Kan, C.-C., Villafranca, J. E., et al. (1999) · Structure · doi:10.1016/s0969-2126(99)80042-2 · Cited by 203

Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines

Traxler, P., Bold, G., Frei, J., Lang, M., Lydon, N., Mett, H., Buchdunger, E., Meyer, T., Mueller, M., & Furet, P. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970124v · Cited by 203

The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases

Tatton, L., Morley, G. M., Chopra, R., & Khwaja, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209321200 · Cited by 174

Structural Modes of Stabilization of Permissive Phosphorylation Sites in Protein Kinases: Distinct Strategies in Ser/Thr and Tyr Kinases

Krupa, A., Preethi, G., & Srinivasan, N. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.04.043 · Cited by 145

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis

Wilson, M. B., Schreiner, S. J., Choi, H.-J., Kamens, J., & Smithgall, T. E. (2002) · Oncogene · doi:10.1038/sj.onc.1206008 · Cited by 136

N 2 -Substituted O 6 -Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2

Hardcastle, I. R., Arris, C. E., Bentley, J., Boyle, F. T., Chen, Y., Curtin, N. J., Endicott, J., Gibson, A. E., Golding, B. T., Griffin, R. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0311442 · Cited by 130

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

Laird, A., & Cherrington, J. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.51 · Cited by 130

Src kinase contributes to the metastatic spread of carcinoma cells

Boyer, B., Bourgeois, Y., & Poupon, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205298 · Cited by 123

A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

Huron, D. R., Gorre, M. E., Kraker, A. J., Sawyers, C. L., Rosen, N. X., & Moasser, M. M. (2003) · PubMed · Cited by 118

Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line

Pengetnze, Y., Steed, M., Roby, K. F., Terranova, P. F., & Taylor, C. C. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.012 · Cited by 107

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-Bis anilino pyrimidines

Beattie, J. F., Breault, G. A., Ellston, R. P. A., Green, S. A., Jewsbury, P. J., Midgley, C. J., Naven, R. T., Minshull, C. A., Pauptit, R. A., Tucker, J. A., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00202-6 · Cited by 88

Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 withO6-Substituted Guanine Derivatives

Gibson, A. E., Arris, C. E., Bentley, J., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020056z · Cited by 85

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

Ashcroft, A. J., Davies, F. E., & Morgan, G. J. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01076-3 · Cited by 78

Protein tyrosine kinases: autoregulation and small-molecule inhibition

Hubbard, S. R. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00383-4 · Cited by 77

Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure−Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity

Schroeder, M. C., Hamby, J. M., Connolly, C. J. C., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004291 · Cited by 53

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase

Ballard, P. G., Bradbury, R. H., Hennequin, L. F., Hickinson, D. M., Johnson, P. D., Kettle, J. G., Klinowska, T. C. M., Morgentin, R., Ogilvie, D., & Olivier, A. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.068 · Cited by 33

Structures of bis(2-methoxyethylcyclopentadienyl) complexes of lanthanide chlorides

Zheng, P.-J., Chen, J., Wu, G., DENG, D. ‐., Hu, J., & Qian, C. (1993) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s010876737809385x · Cited by 32

Drug repurposing: progress, challenges and recommendations

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718

The target landscape of clinical kinase drugs

Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708

Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors

Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607

Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314